Comparison Overview

Genentech

VS

Gilead Sciences

Genentech

1 Dna Way, South San Francisco, California, 94080, US
Last Update: 2025-12-09
Between 750 and 799

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 17,817
Subsidiaries: 50
12-month incidents
0
Known data breaches
0
Attack type number
0

Gilead Sciences

333 Lakeside Drive, Foster City, CA, US, 94404
Last Update: 2025-12-09
Between 750 and 799

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 14,615
Subsidiaries: 10
12-month incidents
1
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/genentech.jpeg
Genentech
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Genentech
100%
Compliance Rate
0/4 Standards Verified
Gilead Sciences
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Genentech in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

Gilead Sciences has 49.25% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History — Genentech (X = Date, Y = Severity)

Genentech cyber incidents detection timeline including parent company and subsidiaries

Incident History — Gilead Sciences (X = Date, Y = Severity)

Gilead Sciences cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/genentech.jpeg
Genentech
Incidents

No Incident

https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
Incidents

Date Detected: 2/2025
Type:Breach
Attack Vector: Human Error (Mailing Error)
Blog: Blog

Date Detected: 05/2020
Type:Cyber Attack
Attack Vector: Phishing, Server Compromise
Blog: Blog

FAQ

Gilead Sciences company demonstrates a stronger AI Cybersecurity Score compared to Genentech company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Gilead Sciences company has historically faced a number of disclosed cyber incidents, whereas Genentech company has not reported any.

In the current year, Gilead Sciences company has reported more cyber incidents than Genentech company.

Neither Gilead Sciences company nor Genentech company has reported experiencing a ransomware attack publicly.

Gilead Sciences company has disclosed at least one data breach, while Genentech company has not reported such incidents publicly.

Gilead Sciences company has reported targeted cyberattacks, while Genentech company has not reported such incidents publicly.

Neither Genentech company nor Gilead Sciences company has reported experiencing or disclosing vulnerabilities publicly.

Neither Genentech nor Gilead Sciences holds any compliance certifications.

Neither company holds any compliance certifications.

Genentech company has more subsidiaries worldwide compared to Gilead Sciences company.

Genentech company employs more people globally than Gilead Sciences company, reflecting its scale as a Biotechnology Research.

Neither Genentech nor Gilead Sciences holds SOC 2 Type 1 certification.

Neither Genentech nor Gilead Sciences holds SOC 2 Type 2 certification.

Neither Genentech nor Gilead Sciences holds ISO 27001 certification.

Neither Genentech nor Gilead Sciences holds PCI DSS certification.

Neither Genentech nor Gilead Sciences holds HIPAA certification.

Neither Genentech nor Gilead Sciences holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N